PH12012501674A1 - Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof - Google Patents

Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Info

Publication number
PH12012501674A1
PH12012501674A1 PH1/2012/501674A PH12012501674A PH12012501674A1 PH 12012501674 A1 PH12012501674 A1 PH 12012501674A1 PH 12012501674 A PH12012501674 A PH 12012501674A PH 12012501674 A1 PH12012501674 A1 PH 12012501674A1
Authority
PH
Philippines
Prior art keywords
levofloxacin
eye drops
dosage
solvate
salt
Prior art date
Application number
PH1/2012/501674A
Other languages
English (en)
Inventor
Koji Sakanaka
Kayoko Sakamoto
Masatsugu Nakamura
Hajime Ibuki
Kouichi Kawazu
Takashi Nagano
Original Assignee
Daiichi Sankyo Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PH12012501674A1 publication Critical patent/PH12012501674A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH1/2012/501674A 2010-02-25 2010-12-16 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof PH12012501674A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25
PCT/JP2010/072685 WO2011104981A1 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用

Publications (1)

Publication Number Publication Date
PH12012501674A1 true PH12012501674A1 (en) 2012-11-05

Family

ID=44506417

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2012/501674A PH12012501674A1 (en) 2010-02-25 2010-12-16 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof
PH1/2016/501747A PH12016501747B1 (en) 2010-02-25 2010-12-16 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2016/501747A PH12016501747B1 (en) 2010-02-25 2010-12-16 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Country Status (16)

Country Link
US (1) US20120316158A1 (https=)
EP (1) EP2540299B1 (https=)
JP (3) JP5600056B2 (https=)
KR (2) KR20130043611A (https=)
CN (1) CN102770141A (https=)
BR (1) BR112012021247A2 (https=)
CA (1) CA2791190C (https=)
EA (1) EA201290827A1 (https=)
ES (1) ES2568647T3 (https=)
MX (1) MX349603B (https=)
MY (1) MY183483A (https=)
NZ (1) NZ602126A (https=)
PH (2) PH12012501674A1 (https=)
SG (1) SG183427A1 (https=)
TW (1) TWI488627B (https=)
WO (1) WO2011104981A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130043611A (ko) * 2010-02-25 2013-04-30 다이이찌 산쿄 가부시키가이샤 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
US7629458B2 (en) * 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
ES2292844T3 (es) * 2001-11-30 2008-03-16 Lg Life Sciences Ltd. Utilizacion de gemifloxacina o sus sales con un antibiotico b-lactamico para la preparacion de medicamentos.
US20050009836A1 (en) * 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use
MX2008010222A (es) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Antibioticos nebulizados para terapia de inhalacion.
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
KR20130043611A (ko) * 2010-02-25 2013-04-30 다이이찌 산쿄 가부시키가이샤 레보플록사신 또는 그의 염 또는 그들의 용매화물을 함유하는 안감염증 치료용 점안제, 안감염증의 치료 방법, 레보플록사신 또는 그의 염 또는 그들의 용매화물, 및 그의 용도

Also Published As

Publication number Publication date
EA201290827A1 (ru) 2013-03-29
TWI488627B (zh) 2015-06-21
KR20130043611A (ko) 2013-04-30
BR112012021247A2 (pt) 2018-04-03
EP2540299B1 (en) 2016-04-13
ES2568647T3 (es) 2016-05-03
SG183427A1 (en) 2012-09-27
PH12016501747B1 (en) 2022-06-22
KR20170070265A (ko) 2017-06-21
JP5600056B2 (ja) 2014-10-01
TW201129364A (en) 2011-09-01
CA2791190C (en) 2017-12-12
JP2011195564A (ja) 2011-10-06
US20120316158A1 (en) 2012-12-13
EP2540299A4 (en) 2013-07-24
JP5674882B2 (ja) 2015-02-25
JP2012162532A (ja) 2012-08-30
MX2012009844A (es) 2012-09-21
PH12016501747A1 (en) 2019-02-11
MY183483A (en) 2021-02-20
AU2010346703A1 (en) 2012-09-20
NZ602126A (en) 2013-10-25
HK1177887A1 (en) 2013-08-30
MX349603B (es) 2017-08-03
JP2013241464A (ja) 2013-12-05
EP2540299A1 (en) 2013-01-02
CA2791190A1 (en) 2011-09-01
CN102770141A (zh) 2012-11-07
WO2011104981A1 (ja) 2011-09-01

Similar Documents

Publication Publication Date Title
MX2019001978A (es) Compuestos antibioticos.
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
NZ593111A (en) Antibacterial compounds
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2019012877A (es) Prevencion, interrupcion y tratamiento de biopeliculas con lisina de bacteriofago.
NZ713621A (en) Compounds and methods of treating infections
WO2015002932A8 (en) Antimicrobial compositions comprising hypochlorous acid and silver
WO2012034077A3 (en) Compositions and methods related to attenuated staphylococcal strains
ZA202002093B (en) Antibacterial compounds
PH12012501674A1 (en) Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof
MY209256A (en) Compounds affecting pigment production and use thereof for treatment of bacterial diseases
MX2014006947A (es) Composiciones antimicrobianas que comprenden dgla, 15-ohepa y/o 15-hetre y metodos de uso de las mismas.
EP2046287A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING INFECTIONS
EP3932917A3 (en) Substituted phenyloxazolidinones for antimicrobial therapy
WO2015112980A3 (en) Dermaseptin-type and piscidin-type antimicrobial peptides
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
MX2016003046A (es) Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
BR112014026861A2 (pt) antígenos de estafilococos coagulase e métodos de seu uso
NZ628927A (en) Compounds and methods for treating candidiasis and aspergillus infections
MX2019006768A (es) Peptidos antimicrobianos.
GB2541840A (en) Ophthalmic composition for the treatment of ocular infection
HK1243951A1 (zh) 抗微生物组合和其在治疗微生物感染中的用途
WO2016108930A3 (en) Antisense antibacterial compounds and methods
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.